How to perform low-budget high-quality research

**SP0016** YOUR VERY FIRST STEPS ON SYSTEMATIC REVIEW

Loreto Carmona, Instituto de Salud Musculosquelética, Research, Madrid, Spain

Systematic reviews (SR) are a type of clinical research, and thus they follow the hypothetical-deductive or scientific method. Their objective is to answer clinical questions and they do it based on a specific structure (protocol) and working through inferences. Interestingly, a SR is a type of study design that can answer all types of questions, from efficacy to incidence. They manage the information from previous studies in a pre-established reproducible way, as unbiased as possible. They provide quick answers. However, they should be performed and interpreted with caution: a poor systematic review is much worse than a narrative review, as it gives the false impression of “science”. This is even worse if the studies were combined in a meta-analysis.

In this lecture, we will review the protocol of a SR, the importance of rephrasing the question, the search strategy, selection criteria, and procedures of studies selection, primary endpoints, and quality and risk of bias. The last part of any SR is the analysis, which is always qualitative, supported by the evidence table, and interpretable with caution: a poor systematic review is much worse than a narrative review, as it gives the false impression of “science”. This is even worse if the studies were combined in a meta-analysis.

We will review some methods to evaluate publication bias, to combine results, and to explore heterogeneity. In this sense, it is essential to note that if we cannot find a valid explanation for heterogeneity, our results may not be valid.

**Disclosure of Interests:** Loreto Carmona Grant/research support from: Abbvie, Actelion, Astellas, BMS, Eisay, Gbbero Pharma, Grünenthal, Lelo Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis and UCB Pharma, Paid instructor for: Novartis


**SP0017** USING AVAILABLE DATASETS TO ANSWER NEW RESEARCH QUESTIONS

Daniel Prieto-Alhambra, University of Oxford, NDORMS, Oxford, United Kingdom

**Background:** Clinical data are continuously recorded in clinical encounters in the form of electronic medical records, registries, audits ans similar databases. Such large datasets are available to researchers, and provide unique opportunities. However, challenges arise from the use of routinely collected data, that need special attention and specific skills to minimise a waste in research.

**Objectives:** To discuss available data sources (data discovery), their advantages and limitations, their uses, and to cover examples of research conducted using routinely collected datasets.

**Methods:** We will discuss a list of data sources at high level (types of data), their main pros and cons, and then cover challenges and solutions through a number of previously published examples.

**Disclosure of Interests:** Daniel Prieto-Alhambra Grant/research support from: Grants from Amgen, UCB Biopharma and Servier outside the submitted work, Consultant for: UCB Biopharma, Speakers bureau: Amgen


**SP0018** WHAT YOU SHOULDN’T MISS FROM THE HPR PROGRAMME AS A CLINICIAN

Maria Bergström, Linköping University, Department of Social and Welfare Studies, Division of Occupational Therapy, Norrköping, Sweden

As a health professional, the EULAR congress is the place where I can get access to new and fresh rheumatology research of good quality. My presentation will take you through the possibilities the congress offers clinicians when it comes to different topics within the area of rheumatology. Further, my aim and hope is to give you a sense of what is in store for you during this year’s EULAR congress. People with rheumatic diseases today live their lives to a great extent having the diagnosis affecting their everyday life. The ability to work, interact with others or engaging in activities they want to, can be limited. So what do we need to know about them in order to provide the best possible treatment and rehabilitation? As a health professional clinician, I look forward to finding some of the answers to this during this congress.

During the EULAR congress, we as health professionals have the possibility to contribute to and acquire research of good quality in rheumatology, on our way to give our patients the best possible treatment. Also, we have the possibility to contribute to the patient’s health, and I look forward to sessions touching health topics such as exercise. The quality of research and the variety of topics during this EULAR congress can give us a bigger set of tools to work with when we get back to our patients and continue our path towards the best possible treatment and health for this big and important group of patients. I hope that this session can provide an overview of what this year’s congress can offer from a clinical perspective.

**Disclosure of Interests:** None declared


**SP0019** PRES HPR: DONT DELAY, COLLABORATE TODAY

Jeannette Cappon1, PReS Committee for Health Professionals1, Department pediatric rehabilitation, Reade Center for rehabilitation and rheumatology2, Dutch Health Professionals in Pediatric Rheumatology3, Reade Center for Rehabilitation and Rheumatology, Pediatric Rehabilitation, 1056AB Amsterdam, Netherlands

**Background:** The Pediatric Rheumatology European Society (PReS) is an international organization based in Europe which is dedicated to advance the care and improve the health and well-being of children and young people with rheumatic conditions, helping them to reach their full potential. Full PReS membership is extended to individuals from all European countries, whether they are within the EU or not, and includes countries in the middle east and from other parts of the world as associate members to enrich the collective experience and knowledge. PReS welcomes every practitioner/researcher in the field of pediatric rheumatology.

The PReS committee for Health Professionals in Pediatric Rheumatology aims to bring together nurses, physical therapists, occupational therapists, social workers, psychologists, podiatrists and other health professionals(HP) to foster dialogue, to set standards of clinical practice, education and research.

Collaboration between PReS and EULAR Health Professionals starts today, here in Madrid.

Collaboration in general starts with a shared goal to work on together. Our young patients of today might be your patients of tomorrow: what should you know about what have been through? Your patients of today might have been our young patients of yesterday: what can we learn from their experiences of the past being a child with a rheumatic condition? Did they receive comprehensive care that sustained into their adulthood?

**Objectives:** To find shared goals between HP Eular and HP PReS to deliver comprehensive care for people with rheumatic diseases during their full life.

To find common interests to discuss between HP Eular and HP PReS

**Methods:** Examples of common interests e.g. supporting self management of pain and health and illness education are presented.

Shared goals for collaboration are proposed and collected from the audience.

Opportunities to connect for Eular HP and PReS HP in Madrid and Prague September 2020 are listed and benefits are mentioned.

**Results:** Health Professionals from Eular and PReS experience common interests and shared goals. Positive relations are expected to develop upcoming years.

**Conclusion:** CollaboRelation between HP Eular and HP PReS can start today

**Disclosure of Interests:** None declared


**SP0020** THE GLOBAL CHALLENGE AND OPPORTUNITY FOR PAEDIATRIC RHEUMATOLOGY

Christian Scott, University of Cape Town, Red Cross War Memorial Children's Hospital, Paediatric Rheumatology, Cape Town, South Africa

**Background:** Poorly developed healthcare systems and the overwhelming burden of communicable diseases have limited the growth and development of Paediatric Rheumatology in non central and less resourced countries. Most children on earth reside in these less resourced environments and suffer from disproportionately poor access to adequate care for paediatric rheumatic diseases. Emerging evidence suggests that rates of rheumatic diseases are not likely to be different to European and North American children but that diseases severity and